A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Nitya RajElizabeth CruzSarah O'ShaughnessyClaudia CalderonJoanne F ChouMarinela CapanuOlivia HeffernanApril DeMoreSippy PunnTiffany LeHaley HauserLeonard B Saltz Diane L Reidy

Published in: JCO oncology practice (2022)

We found minimal pain with octLAR and lanreotide and no significant pain score differences between the two. Patients indicating a drug preference trended toward favoring octLAR.

Keyphrases

neuroendocrine tumors
chronic pain
end stage renal disease
ejection fraction
neuropathic pain
newly diagnosed
chronic kidney disease
peritoneal dialysis
emergency department
spinal cord
combination therapy
drug induced
electronic health record